Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1991-12-02
1995-03-07
Cintins, Marianne M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514319, 514358, 514211, 5142222, 514200, 514456, 546196, 546205, A61K 31445, A61K 3144, A61K 31545, C07D40100
Patent
active
053958420
ABSTRACT:
Inhibitors of sex steroid activity, for example those having the general structure ##STR1## may be used as part of a pharmaceutical composition to provide antiestrogenic effects and/or to suppress estrogen synthesis. Such pharmaceutical compositions are useful for the treatment of breast cancer or other diseases whose progress is aided by activation of sex steroid receptors.
REFERENCES:
patent: 2875199 (1959-02-01), Cella
patent: 3321483 (1967-05-01), Crenshaw et al.
patent: 3396169 (1966-08-01), Lednicer et al.
patent: 3471520 (1969-10-01), Irmscher et al.
patent: 3597431 (1971-08-01), Coppola et al.
patent: 3995060 (1976-11-01), Neri
patent: 4094994 (1978-06-01), Schonenberger
patent: 4139638 (1979-02-01), Neri
patent: 4161540 (1979-07-01), Neri
patent: 4368080 (1983-05-01), Crossley
patent: 4472382 (1984-09-01), Labrie
patent: 4659516 (1987-04-01), Bowler
patent: 4659695 (1987-04-01), Labrie
patent: 4732912 (1988-03-01), Pilgrim
patent: 4751240 (1988-06-01), Bowler
patent: 4760061 (1988-07-01), Edwards
patent: 4904661 (1990-02-01), Pilgrim et al.
patent: 4950684 (1990-08-01), Koszyk
patent: 4963568 (1990-10-01), Schoenleber et al.
patent: 4975455 (1990-12-01), Brion et al.
patent: 5021432 (1991-06-01), Yamanaka et al.
patent: 5098903 (1992-03-01), Magarian et al.
patent: 5204337 (1993-04-01), Labrie et al.
Asselin, J., Labrie, F. (1978) Effect of estradiol and prolactin on steroid receptor levels in 7-12-dimethylbenz(a)anthracene-induced mammary tumors and uterus in the rat. J. Steroid Biochem. 9: 1079-1081.
Auchus R J, Covey D F (1986) Mechanism-base inactivation of 17.beta.-20.alpha.-hydroxysteroid dehydrogenase by an acetylenic secoestradiol. Biochemistry 25: 7295-7300.
Bhatnagar Y M, Chin C C, Warren J C (1978) Synthesis of 4-bromoacetamidoestrone methyl ether and study of the steroid binding site of human placental estradiol 17.beta.--dehydrogenase. J Biol Chem 253: 811-815.
Blickenstaff R T, Foster E, Gerzon K, Young P (1985) Synthesis of some analogs of estradiol. Steroids 46: 889-902.
Bucourt, R., Vignau, M., Torelli, V. (1978) New biospecific adsorbents for the purification of estradiol receptor. J. Biol. Chem. 253:8221-8228.
Chin C C, Warren J C (1975) Synthesis of 16.alpha.-bromoacetoxyestradiol 3-methyl ether and study of the steroid binding site of human placental estradiol 17.beta.-dehydrogenase. J. Biol. Chem. 250: 7682-7686.
Chin C C, Asmar P, Warren J C (1980) Synthesis of 2-bromoacetamidoestrone methyl ether and study of the steroid-binding site of human placental estradiol 17.beta.-dehydrogenase. J. Biol. Chem. 255: 3660-3664.
Durani, N., Jain, R., Saeed, A., Dikshit, D. K., Durani, S., Kapil, R. S. (1989) Structure-activity relationship of antiestrogens: a study using triarylbutenone, benzofuran and triarylfuran analogues as models for triarylethylenes and triarylpropenones. J. Med. Chem. 32: 1700-1707.
Furr B J A, Valcaccia B, Curry B, Woodburn J R, Chesterson G, Tucker H (1987) ICI 176,334: a novel non-steroidal, peripherally selective antiandrogen. J. Endocr. 113: R7-R9.
Jordan, V. C., Koch, R. (1989) Regulation of prolactin synthesis in vivo by estrogenic and antiestrogenic derivatives of estradiol and estrone. Endocrinology 124: 1717-1726.
Klijn, J. G. M., de Jong, F. H., Blankenstein, M. A. (1984) Long-term LHRH-agonist treatment for metastatic breast cancer insingle and combined drug regimens. J. Steroid Biochem. 20 (6B): 1381, No A33 (Abst.).
Mouridsen, H., Palshof, T. (1978) Tamoxifen in advanced breast cancer. Cancer Treatm. Rev. 5: 131-141.
Saeed, A., Sharma, A. P., Durani, N., Jain, R., Duranis, S., Kapil, R. S. (1990) Structure-activity relationship of antiestrogens. Studies on 2, 3-diaryl-1-benzopyrans. J. Med. Chem. 33: 3210-3216.
Sharma, A. P., Saeed, A., Durani, S., Kapil, R. S. (1990) Structure-activity relationship of antiestrogens. Effect of the side chain and its position on the activity of 2,3-diaryl-2H-1-benzopyrans. J. Med. Chem. 33: 3216-3222.
Sharma, A. P., Saeed, A., Durani, S., Kapil, R. S. (1990) Structure-activity relationship of antiestrogens. Phenolic analogues of 2,3-diaryl-2H-1-benzopyrans. J. Med. Chem. 33: 3222-3229.
Simard, J., Labrie, F. (1985) Keoxifene shown pure antiestrogenic activity in pituitary gonadotrophs, Mol. Cell. Endocrinol. 39: 141-144.
Simard, J., Dauvois, S., Haagensen, D. E., Levesque, C., Merand, Y., Labrie, F. (1990) Regulation of progesterone-binding breast cyst protein GCDFG-24 secretion by estrogens and androgens in human breast cancer cells: a new marker of steroid action in breast cancer. Endrocrinology 126: 3223-3231.
Simard, J., Labrie, C., Hubert, J. F., Labrie, F. (1988) Modulation by sex steroids and [D-Trp6, des-gly-NH210] luteinizing hormone (LH)-releasing hormone ethylamide of .alpha.-subunit and LH.beta. messenger ribonucleic acid levels in the rat anterior pituitary gland. Mol. Cell. Endocrinol. 2: 775-784.
Thomas, J. L., Strickler, R. C. (1983) Human placental 17.beta.-estradiol dehydrogenase and 20.alpha.-hydroxysteroid dehydrogenase. J. Biol. Chem. 258: 1587-1590.
Thomas, J. L., LaRochelle, M. C., Covey, D. F., Strickler, R. C. (1983) Inactivation of human placental 17.beta.,20.alpha.-hydroxysteroid dehydrogenase by 16-methylene estrone, an affinity alkylator enzymatically generated from 16-methylene estradiol 17.beta.-J. Biol. Chem. 258: 11500-11508.
Tobias, B., Covey, D. F., Strickler, R. C. (1982) Inactivation of human placental 17.beta.-estradiol dehydrogenase and 20.alpha.-hydroxysteroid dehydrogenase with active sex-directed 17.beta.-propynyl-substituted progestin analogs. J. Biol. Chem. 257: 2783-2786.
von Angerer E, Knebel N, Kager M, Ganss B (1990) 1-(Aminoalkyl)-2-phenylindoles as novel pure estrogen antagonists. J. Med. Chem. 33:2635-2640.
von Angerer, E., Prekajac, J., Strohmeier, J. (1984) 2-Phenylindoles. Relationship between structure, estrogen receptor affinity, and mammary tumor inhibiting activity in the rat. J. Med. Chem. 27: 1439-1447.
Wakeling A E, Dukas M, Bowler J. (1991) A potent specific pure antiestrogen with clinical potential. Cancer Res. 51: 3867-3873.
Wakeling, A. E., Bowler, J. (1988) Biology and mode of action of pure antioestrogens. J. Steroid Biochem. 30: 141-147.
Wakeling, A. E., Bowler, (1987) Steroidal pure antioestrogens. J. Endocr, 112: R7-R10.
Dhar, et al., Contraception, vol. 44, No. 4, (1991) pp. 461-472.
Stoessel, et al., Journal of Steroid Biochem., vol. 25, No. 5A (1986) pp. 677-682.
Crenshaw, et al., Journal of Medicinal Chemistry, vol. 14, No. 2 (1971) pp. 1185-1190.
Pruitt, et al., Organic Prep. and Proc. Int'l, vol. 22, No. 2 (1990) pp. 235-244.
Jones, et al., "Synthesis and Antiestrogenic Activity of (3,4-Dihydro-2-(4-Methoxyphenyl)-1-Naphthalenyl)(4-(2-(1-Pyrrolidinyl Ethoxy)-Phenyl) Methanone, Meth Anesulfonic Acid Salt", Journal of Medicinal Chemistry, vol. 22, No. 8 (1979).
CA: 113(23)-No. 211775w p. 744, Dec. 1990-Sharma et al.
CA: 117(9)-No. 90146p p. 90147 Aug. 1992-Kapil et al.
CA: 86(1)-No. 5271z p. 5280 Jan. 1977-Badran et al.
CA: 107 No. 154111(b) p. 678 Oct. 1987-Alberola et al.
Labrie Fernand
Merand Yves
Cintins Marianne M.
Criares T. J.
Endorecherche Inc.
LandOfFree
Anti-estrogenic compounds and compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-estrogenic compounds and compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-estrogenic compounds and compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1406165